| Literature DB >> 31095633 |
Carl Delfin1,2, Hedvig Krona3, Peter Andiné1,4,5, Erik Ryding6, Märta Wallinius1,2,3, Björn Hofvander3,7.
Abstract
One of the primary objectives in forensic psychiatry, distinguishing it from other psychiatric disciplines, is risk management. Assessments of the risk of criminal recidivism are performed on a routine basis, as a baseline for risk management for populations involved in the criminal justice system. However, the risk assessment tools available to clinical practice are limited in their ability to predict recidivism. Recently, the prospect of incorporating neuroimaging data to improve the prediction of criminal behavior has received increased attention. In this study we investigated the feasibility of including neuroimaging data in the prediction of recidivism by studying whether the inclusion of resting-state regional cerebral blood flow measurements leads to an incremental increase in predictive performance over traditional risk factors. A subsample (N = 44) from a cohort of forensic psychiatric patients who underwent single-photon emission computed tomography neuroimaging and clinical psychiatric assessment during their court-ordered forensic psychiatric investigation were included in a long-term (ten year average time at risk) follow-up. A Baseline model with eight empirically established risk factors, and an Extended model which also included resting-state regional cerebral blood flow measurements from eight brain regions were estimated using random forest classification and compared using several predictive performance metrics. Including neuroimaging data in the Extended model increased the area under the receiver operating characteristic curve (AUC) from .69 to .81, increased accuracy from .64 to .82 and increased the scaled Brier score from .08 to .25, supporting the feasibility of including neuroimaging data in the prediction of recidivism in forensic psychiatric patients. Although our results hint at potential benefits in the domain of risk assessment, several limitations and ethical challenges are discussed. Further studies with larger, carefully characterized clinical samples utilizing higher-resolution neuroimaging techniques are warranted.Entities:
Mesh:
Year: 2019 PMID: 31095633 PMCID: PMC6522126 DOI: 10.1371/journal.pone.0217127
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Regions-of-interest.
An overview of the regions-of-interest (ROIs) used in the current study. Numbers refer to centimeters above/below the orbitomeatal line. C = cerebellum, T = temporal lobe, F = frontal lobe, P = parietal lobe.
Detailed overview of sample clinical characteristics.
| All ( | Non-recidivists ( | Recidivists ( | |||
|---|---|---|---|---|---|
| Mean (± SD) or | Mean (± SD) or | Mean (± SD) or | |||
| Patients still under forensic psychiatric care | 13 (30%) | 8 (29%) | 5 (31%) | -0.19 | 0.898 |
| Number of days under forensic psychiatric care | 1746.77 (± 1639.04) | 1765.93 (± 1676.93) | 1713.25 (± 1624.04) | 0.1 | 0.919 |
| Time at risk (days) | 3622.86 (± 1494.5) | 3427 (± 1678) | 3965.62 (± 1066.6) | -1.3 | 0.201 |
| Psychotic disorder | 30 (68%) | 20 (71%) | 10 (62%) | 0.61 | 0.596 |
| Mood disorder | 5 (11%) | 3 (11%) | 2 (12%) | -0.18 | 0.967 |
| Personality disorder | 1 (2%) | 0 (0%) | 1 (6%) | -1.34 | 0.246 |
| Cognitive disorder | 3 (7%) | 2 (7%) | 1 (6%) | 0.11 | 0.998 |
| Neurodevelopmental disorder | 5 (11%) | 3 (11%) | 2 (12%) | -0.18 | 0.967 |
| Antipsychotic | 27 (61%) | 19 (68%) | 8 (50%) | 1.17 | 0.261 |
| Antidepressant | 13 (30%) | 6 (21%) | 7 (44%) | -1.56 | 0.131 |
| Benzodiazepine sedatives | 20 (45%) | 12 (43%) | 8 (50%) | -0.46 | 0.657 |
| Non-benzodiazepine sedatives | 16 (36%) | 10 (36%) | 6 (38%) | -0.12 | 0.923 |
| Anticholinergic | 10 (23%) | 9 (32%) | 1 (6%) | 1.97 | 0.052 |
| Frontal (right) | 106.61 (± 4.06) | 106.46 (± 4.52) | 106.88 (± 3.22) | -0.35 | 0.728 |
| Frontal (left) | 106.64 (± 3.94) | 106.82 (± 4.34) | 106.31 (± 3.22) | 0.44 | 0.66 |
| Parietal (right) | 104.82 (± 3.2) | 106.11 (± 2.74) | 102.56 (± 2.71) | 4.16 | < .001 |
| Parietal (left) | 103.45 (± 3.59) | 104.18 (± 4.11) | 102.19 (± 1.94) | 2.17 | 0.036 |
| Temporal (right) | 102.57 (± 3.39) | 102.07 (± 3.67) | 103.44 (± 2.73) | -1.4 | 0.168 |
| Temporal (left) | 101.52 (± 2.57) | 101.04 (± 2.85) | 102.38 (± 1.75) | -1.93 | 0.06 |
| Cerebellum (right) | 119.64 (± 4.69) | 120.68 (± 4.6) | 117.81 (± 4.4) | 2.04 | 0.049 |
| Cerebellum (left) | 119.82 (± 5.01) | 120.68 (± 4.92) | 118.31 (± 4.95) | 1.53 | 0.136 |
| Age at forensic psychiatric investigation | 37.84 (± 14.79) | 42.29 (± 16.28) | 30.06 (± 6.95) | 3.46 | 0.001 |
| Age at first crime | 30.34 (± 14.09) | 34.57 (± 15.69) | 22.94 (± 5.81) | 3.52 | 0.001 |
| PCL:SV Total Score | 10.3 (± 5.97) | 9.25 (± 5.6) | 12.12 (± 6.32) | -1.51 | 0.142 |
| Male sex | 39 (89%) | 25 (89%) | 14 (88%) | 0.18 | 0.967 |
| Substance use disorder | 22 (50%) | 12 (43%) | 10 (62%) | -1.25 | 0.238 |
| Cluster B personality disorder | 7 (16%) | 1 (4%) | 6 (38%) | -2.96 | 0.008 |
| Educational attainment | 40 (91%) | 26 (93%) | 14 (88%) | 0.59 | 0.732 |
| Mental disorder in first-degree relative | 13 (30%) | 7 (25%) | 6 (38%) | -0.87 | 0.459 |
| Previous criminality | 28 (64%) | 17 (61%) | 11 (69%) | -0.53 | 0.608 |
PCL:SV = Psychopathy Checklist: Screening Version.
aAt the end of follow-up on 31st of December 2013.
Fig 2Variable importance.
Variable importance measured as the scaled mean decrease in accuracy of each variable in the Baseline and Extended model. A higher value confers a higher decrease in the accuracy of the model, should that variable be omitted.
Fig 3Partial dependence plots.
Partial dependence plots for the eight most important (in terms of scaled mean decrease in accuracy) variables in each model. A higher value on the y-axis confers a higher probability of being predicted as a recidivist for the corresponding value on the x-axis for that variable.